ES2731725T3 - Método para evaluar y predecir la eficacia del tratamiento del cáncer de mama con un inhibidor de la topoisomerasa I de acción prolongada - Google Patents

Método para evaluar y predecir la eficacia del tratamiento del cáncer de mama con un inhibidor de la topoisomerasa I de acción prolongada Download PDF

Info

Publication number
ES2731725T3
ES2731725T3 ES13802833T ES13802833T ES2731725T3 ES 2731725 T3 ES2731725 T3 ES 2731725T3 ES 13802833 T ES13802833 T ES 13802833T ES 13802833 T ES13802833 T ES 13802833T ES 2731725 T3 ES2731725 T3 ES 2731725T3
Authority
ES
Spain
Prior art keywords
treatment
long
inhibitor
level
tumor marker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13802833T
Other languages
English (en)
Spanish (es)
Inventor
Yen Chia
Ute Hoch
Alison Hannah
Michael Eldon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Application granted granted Critical
Publication of ES2731725T3 publication Critical patent/ES2731725T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4725Mucins, e.g. human intestinal mucin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ES13802833T 2012-11-28 2013-11-27 Método para evaluar y predecir la eficacia del tratamiento del cáncer de mama con un inhibidor de la topoisomerasa I de acción prolongada Active ES2731725T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261730900P 2012-11-28 2012-11-28
PCT/US2013/072205 WO2014085571A1 (en) 2012-11-28 2013-11-27 Method for assessing and predicting efficacy of breast cancer treatment with a long-acting topoisomerase i inhibitor

Publications (1)

Publication Number Publication Date
ES2731725T3 true ES2731725T3 (es) 2019-11-18

Family

ID=49753531

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13802833T Active ES2731725T3 (es) 2012-11-28 2013-11-27 Método para evaluar y predecir la eficacia del tratamiento del cáncer de mama con un inhibidor de la topoisomerasa I de acción prolongada

Country Status (10)

Country Link
US (2) US10132810B2 (enExample)
EP (1) EP2926137B1 (enExample)
JP (1) JP6284541B2 (enExample)
KR (1) KR102120510B1 (enExample)
CN (1) CN104813167B (enExample)
AU (1) AU2013352223B2 (enExample)
CA (1) CA2890082C (enExample)
ES (1) ES2731725T3 (enExample)
MX (1) MX366911B (enExample)
WO (1) WO2014085571A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106191022B (zh) * 2016-02-22 2019-08-20 叶尚勉 一种肿瘤特异抗原及其应用
CA3112778A1 (en) 2018-09-17 2020-03-26 The Children's Hospital Of Philadelphia Polymer-based macromolecular prodrugs
CN112102914A (zh) * 2020-09-25 2020-12-18 复旦大学附属肿瘤医院 曲妥珠单抗生物类似药的评价方法及系统

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9704444D0 (en) * 1997-03-04 1997-04-23 Isis Innovation Non-invasive prenatal diagnosis
US6355623B2 (en) * 1998-09-24 2002-03-12 Hopital-Sainte-Justine Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
US20020103141A1 (en) * 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
CA2537336C (en) 2003-09-17 2013-02-26 Nektar Therapeutics Al, Corporation Multi-arm polymer prodrugs
WO2005074633A2 (en) * 2004-02-03 2005-08-18 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
JP5276982B2 (ja) * 2005-08-26 2013-08-28 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ オキシトシンの投与による頭痛の処置のための方法
KR20080091829A (ko) * 2006-02-09 2008-10-14 엔존 파마슈티컬즈, 인코포레이티드 유방암, 대장암, 췌장암, 난소암 및 폐암 치료용 7―에틸―10―히드록시캄포테신의 다분지형 고분자 접합체
US20110151580A1 (en) * 2007-11-06 2011-06-23 University Health Network Method for the detection of breast cancer by determining alcam and/or bcam levels in a patient
LT2349346T (lt) * 2008-09-23 2019-09-25 Nektar Therapeutics Kamptotecino provaistų (pvz., peg-irinotekano) metronominio dozavimo būdas
PT2501413T (pt) 2009-11-18 2019-07-10 Nektar Therapeutics Formas de sal de ácido de conjugados de polímero-fármaco
JP2013526852A (ja) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
WO2012031320A1 (en) 2010-09-06 2012-03-15 Peter Maccallum Cancer Institute Cancer diagnostic
EP2771034B1 (en) 2011-10-25 2018-08-08 Nektar Therapeutics Topoisomerase-i and-ii inhibitors for use in the treatment of patients suffering from cancer

Also Published As

Publication number Publication date
EP2926137A1 (en) 2015-10-07
MX366911B (es) 2019-07-30
KR102120510B1 (ko) 2020-06-08
MX2015006733A (es) 2015-08-14
CA2890082A1 (en) 2014-06-05
WO2014085571A1 (en) 2014-06-05
JP2016502083A (ja) 2016-01-21
US10132810B2 (en) 2018-11-20
CN104813167B (zh) 2019-04-09
EP2926137B1 (en) 2019-05-29
US20150309032A1 (en) 2015-10-29
AU2013352223B2 (en) 2019-07-18
AU2013352223A1 (en) 2015-05-21
CA2890082C (en) 2021-07-06
CN104813167A (zh) 2015-07-29
US20190049450A1 (en) 2019-02-14
KR20150089013A (ko) 2015-08-04
JP6284541B2 (ja) 2018-02-28

Similar Documents

Publication Publication Date Title
US11844795B2 (en) Combination therapy for cancer treatment
ES3009356T3 (en) Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors
US20230372499A1 (en) Dendrimer compositions and methods for drug delivery
AU2016287508B2 (en) Methods of treating solid tumors using nanoparticle MTOR inhibitor combination therapy
Maity et al. Targeting the epidermal growth factor receptor with molecular degraders: state-of-the-art and future opportunities
US20240082436A1 (en) Synergistic cancer treatment
ES2731725T3 (es) Método para evaluar y predecir la eficacia del tratamiento del cáncer de mama con un inhibidor de la topoisomerasa I de acción prolongada
US20170165322A1 (en) Peptide and small molecule agonists of epha and their uses in disease
Lee et al. Pheophorbide A and SN38 conjugated hyaluronan nanoparticles for photodynamic-and cascadic chemotherapy of cancer stem-like ovarian cancer
Lian et al. RJT-101, a novel camptothecin derivative, is highly effective in the treatment of melanoma through DNA damage by targeting topoisomerase 1
ES2458818T3 (es) Métodos para evaluar la actividad de una composición de polisacárido
WO2024061848A1 (en) Novel compositions based on polyinosinic-polycytidylic acid
US10159659B2 (en) Predicting response to cancer therapy
Xie et al. Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRAS G12D Inhibitor
JP6138140B2 (ja) 癌患者の治療
TW201713362A (zh) 選擇性抑制腸羧酸酯酶2酵素活性的組成物及方法
CA2993451C (en) Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
TW202600140A (zh) Wee1抑制劑及拓樸異構酶1抑制劑之組合
Eathiraj et al. Targeting PI3K pathway dependent endometrial tumors with allosteric AKT inhibitors, ARQ 092 and ARQ 751
Makeyev et al. Topoisomerase I inhibitors: current use and prospects